Brokerages Set Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) PT at $29.50

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has been assigned a consensus recommendation of “Hold” from the eight analysts that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $29.50.

Several analysts have recently weighed in on AMPH shares. Wells Fargo & Company reduced their price objective on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research report on Monday, December 29th. Needham & Company LLC cut their price target on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Finally, Barclays initiated coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 price target for the company.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $19.00 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.90 and a current ratio of 4.02. Amphastar Pharmaceuticals has a fifty-two week low of $17.03 and a fifty-two week high of $31.26. The firm has a market capitalization of $862.03 million, a PE ratio of 9.36, a price-to-earnings-growth ratio of 1.63 and a beta of 0.93. The stock’s 50-day simple moving average is $25.29 and its 200-day simple moving average is $26.01.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, February 26th. The company reported $0.73 earnings per share for the quarter, missing the consensus estimate of $0.97 by ($0.24). The business had revenue of $183.11 million for the quarter, compared to analysts’ expectations of $190.48 million. Amphastar Pharmaceuticals had a return on equity of 17.58% and a net margin of 13.63%. As a group, equities research analysts forecast that Amphastar Pharmaceuticals will post 3.49 EPS for the current fiscal year.

Institutional Trading of Amphastar Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. New York State Common Retirement Fund lifted its stake in Amphastar Pharmaceuticals by 86.4% in the third quarter. New York State Common Retirement Fund now owns 90,169 shares of the company’s stock valued at $2,403,000 after buying an additional 41,800 shares during the last quarter. Capital Fund Management S.A. purchased a new position in shares of Amphastar Pharmaceuticals during the second quarter worth approximately $931,000. SummerHaven Investment Management LLC purchased a new position in shares of Amphastar Pharmaceuticals during the third quarter worth approximately $1,018,000. Rice Hall James & Associates LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at $3,447,000. Finally, Quantbot Technologies LP increased its holdings in shares of Amphastar Pharmaceuticals by 188.8% in the 2nd quarter. Quantbot Technologies LP now owns 60,955 shares of the company’s stock valued at $1,400,000 after acquiring an additional 39,846 shares during the period. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.